Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    GALAD Model for Hepatocellular Carcinoma (HCC)

    Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD).
    Favorite
    When to Use
    Why Use

    Use in patients with chronic liver disease (CLD).

    • Estimates risk that a CLD patient has HCC using only tumor markers and demographics (i.e., no imaging).
    • AUROC was 0.92 in one validation study (Best 2016).
    Female
    Male
    years
    %
    ng/mL
    ng/mL

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    Use clinical judgment to determine how closely to surveil patients for HCC.

    Management

    No guidelines currently exist for thresholds at which to image patients based on GALAD results. One large prospective study suggests patients with AFP ≥10 ng/mL or AFP-L3 ≥5% be imaged with CT or MRI every 3-6 months (Kumada 2011).

    About the Creator
    Dr. Philip J. Johnson
    Are you Dr. Philip J. Johnson?